Bioxcel therapeutics reports third quarter 2021 financial results and recent operational highlights

Plans for commercial and launch readiness advancing for bxcl501 orally dissolving film, for the acute treatment of agitation associated with schizophrenia and bipolar disorders i and ii, ahead of january 5, 2022 pdufa date

BTAI Ratings Summary

BTAI Quant Ranking